ECSP034672A - Derivados de quinuclidina novedosos y composiciones medicinales que los contienen - Google Patents

Derivados de quinuclidina novedosos y composiciones medicinales que los contienen

Info

Publication number
ECSP034672A
ECSP034672A EC2003004672A ECSP034672A ECSP034672A EC SP034672 A ECSP034672 A EC SP034672A EC 2003004672 A EC2003004672 A EC 2003004672A EC SP034672 A ECSP034672 A EC SP034672A EC SP034672 A ECSP034672 A EC SP034672A
Authority
EC
Ecuador
Prior art keywords
group
hydrogen
carbon atoms
lower alkyl
substituted
Prior art date
Application number
EC2003004672A
Other languages
English (en)
Inventor
Albero Maria Antonia Buil
Forner Maria Dolors Fernandez
Maria Quinones
Original Assignee
Almirall Prodesfarma A G
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma A G filed Critical Almirall Prodesfarma A G
Publication of ECSP034672A publication Critical patent/ECSP034672A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de fórmula (I): en donde B es un anilo fenilo, un grupo heteroaromático de 5 a 10 miembros que contiene un grupo benzo[1, 3] dioxolilo, o bifenilo, R1, R2 Y R3 cada uno independientemente representa un átomo de hidrógeno o halógeno, o un grupo hidroxi, un grupo fenilo, -OR7. -SR7, -NR7R8, -grupo alquilo inferior sustituido o sin sustituir, en donde R7 y R8 cada uno independientemente representa un átomo de hidrógeno, un grupo alquilo inferior recto o ramificado o conjuntamente forman un anilo alicíclico o R1 y R2 conjuntamente forman un anillo aromático o alicíclico o un grupo heterocíclico. n es un enteri de 0 a 4; A representa un grupo seleccionado entre - CH2-,CH=CR9-, CR9=CH-, CR9R10-, C0-, -=-, -S-, -S(0)-, -S(0)2 y-NR9-, en donde R9 y R10 cada uno independientemente representa un átomo de hidrógeno, un grupo alquilo recto o ramificado de alquilo inferior o conjuntamente forman un anillo alicíclico, m es un entero de 0 a 8, siempre que cuando m=0, A no es -CH2-, Pes un entero de 1 a 2 y la sustitución del anillo bicíclico de azonia puede ser en la posición 2, 3 0´ 4 incluyendo todas las configuraciones posibles de los carbonos asimétricos; R4 representa un grupo de estructura. En donde R11 Representa un átomo de hidrogeno o halógeno, un grupo hidroxi, un grupo alcoxi, un grupo nitro, un grupo ciano, -C02R12, o NR12R13, en donde R12 y R13 son idénticos o diferentes y son seleccionados entre hidrógeno y grupos de alquilo inferior recto o ramificado, sustituido o no sustituido; R5 representa un grupo alquilo de 1 a 7 átomos de carbono, un grupo alquenilo que contiene 2 a 7 átomos de carbono, un grupo alquinilo que contiene 2 a 7 átomos de carbono , un grupo cicloalquilo de 3 a 7 átomos de carbono, o un grupo de la fórmula en donde q= 1 0 2 y R11 es tal como se define anteriormente; R6 representa un átomo de hidrógeno, un grupo hidroxi, un grupo metilo, o un grupo CH2OH. El carbono asimétrico en la posición alfa con respecto al grupo ester, que es sustituido por R4, R5 y R6 puede tener una configuración R 0 S; X -representa un anion farmacéuticamente aceptable de un ácido mono o polivalente.
EC2003004672A 2000-12-28 2003-06-25 Derivados de quinuclidina novedosos y composiciones medicinales que los contienen ECSP034672A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200003130 2000-12-28

Publications (1)

Publication Number Publication Date
ECSP034672A true ECSP034672A (es) 2003-08-29

Family

ID=8496180

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004672A ECSP034672A (es) 2000-12-28 2003-06-25 Derivados de quinuclidina novedosos y composiciones medicinales que los contienen

Country Status (33)

Country Link
US (4) US7122558B2 (es)
EP (1) EP1353919B1 (es)
JP (1) JP4295985B2 (es)
KR (1) KR100869721B1 (es)
CN (1) CN1250545C (es)
AR (1) AR032072A1 (es)
AT (1) ATE334128T1 (es)
AU (1) AU2002238471B2 (es)
BG (1) BG66162B1 (es)
BR (1) BR0116624A (es)
CA (1) CA2433128C (es)
CY (1) CY1105719T1 (es)
CZ (1) CZ301209B6 (es)
DE (1) DE60121813T2 (es)
DK (1) DK1353919T3 (es)
EC (1) ECSP034672A (es)
EE (1) EE05404B1 (es)
ES (1) ES2266291T3 (es)
HU (1) HUP0303524A3 (es)
IL (2) IL156558A0 (es)
MX (1) MXPA03005862A (es)
MY (1) MY136067A (es)
NO (1) NO328772B1 (es)
NZ (1) NZ526674A (es)
PE (1) PE20020721A1 (es)
PL (1) PL363807A1 (es)
PT (1) PT1353919E (es)
RU (1) RU2282629C2 (es)
SI (1) SI1353919T1 (es)
SK (1) SK287414B6 (es)
UA (1) UA75626C2 (es)
WO (1) WO2002053564A2 (es)
ZA (1) ZA200305008B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
RU2296762C2 (ru) 2000-12-22 2007-04-10 Альмиралль Продесфарма Аг Карбаматы хинуклидина, способы их получения и фармацевтическая композиция на их основе
DK1353919T3 (da) * 2000-12-28 2006-11-20 Almirall Prodesfarma Ag Hidtil ukendte quinuclidinderivater og medicinale sammensætninger indeholdende samme
GB0118373D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
AU2002345266B2 (en) * 2002-07-08 2009-07-02 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
US7410993B2 (en) * 2002-08-09 2008-08-12 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane deriviatives useful as muscarinic receptor antagonists
TWI295669B (en) 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CN100436414C (zh) * 2003-04-11 2008-11-26 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
CN100445281C (zh) * 2003-05-02 2008-12-24 诺瓦提斯公司 与毒蕈碱性m3受体结合的奎宁环衍生物
US7358244B2 (en) 2003-05-28 2008-04-15 Theravance, Inc. Azabicycloalkane compounds
WO2005007645A1 (en) 2003-07-11 2005-01-27 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
US20050026887A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a steroid
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
EP1747219A4 (en) * 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AU2005247106B2 (en) * 2004-05-31 2010-11-11 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and PDE4 inhibitors
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
WO2006035303A1 (en) * 2004-09-29 2006-04-06 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
CA2585122A1 (en) * 2004-10-25 2006-05-04 Schering Corporation M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US8258141B2 (en) 2006-04-21 2012-09-04 Novartis Ag Organic compounds
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
RS51644B (sr) 2007-01-10 2011-10-31 Irm Llc. Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
BRPI0806972A2 (pt) * 2007-02-09 2014-04-08 Astellas Pharma Inc Composto cíclico contendo ponte azo
AU2008215924B2 (en) * 2007-02-15 2011-04-21 Pulmagen Therapeutics (Synergy) Limited Heterocyclic derivatives as M3 muscarinic receptors
CA2685546A1 (en) 2007-05-07 2008-11-13 Novartis Ag Organic compounds
JP5656288B2 (ja) 2007-09-07 2015-01-21 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ムスカリン受容体アンタゴニストとして有用なグアジニン含有化合物
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
PL2444120T3 (pl) 2007-12-10 2018-02-28 Novartis Ag Spirocyklicze analogi amiloridu jako blokery ENac
EP2222637A1 (en) 2007-12-14 2010-09-01 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
GB0808707D0 (en) * 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
GB0808708D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
AU2008356409B2 (en) 2008-05-13 2012-01-19 Astrazeneca Ab Quinuclidine derivatives as muscarinic M3 receptor antagonists
JP2011522860A (ja) 2008-06-10 2011-08-04 ノバルティス アーゲー 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
KR20120089643A (ko) 2009-08-12 2012-08-13 노파르티스 아게 헤테로시클릭 히드라존 화합물, 및 암 및 염증을 치료하기 위한 그의 용도
NZ620020A (en) 2009-08-17 2015-06-26 Intellikine Llc Heterocyclic compounds and uses thereof
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP2834246B1 (en) 2012-04-03 2021-07-28 Novartis AG Combination products with tyrosine kinase inhibitors and their use
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
BR112016000629B1 (pt) * 2013-07-13 2023-10-31 Beijing Showby Pharmaceutical Co., Ltd. Compostos de quinina e isômeros ópticos, método de preparação e utilização médica dos mesmos
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
BR112016023967A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
EA201692140A1 (ru) 2014-04-24 2017-04-28 Новартис Аг Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы
BR112016024533A8 (pt) 2014-04-24 2021-03-30 Novartis Ag derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
CA3139634A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
EP4021572A1 (en) 2019-08-28 2022-07-06 Novartis AG Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4465834A (en) * 1965-09-20 1984-08-14 Fmc Corporation Anticholinergic drugs
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
US4082756A (en) 1971-04-16 1978-04-04 Colgate-Palmolive Company Quaternary quinuclidinium carbamates and thiocarbamates
JPS57500735A (es) * 1980-06-03 1982-04-30
US4431627A (en) 1980-06-03 1984-02-14 Research Corporation Gamma-emitting receptor-binding 3-quinuclidinyl glycolates; methods of preparation thereof and imaging and assay methods utilizing same
FR2539135B1 (fr) * 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
IL72788A (en) * 1984-08-28 1989-07-31 Israel State Bis quaternary oxy-bis methylene(or trimethylene)bis-n-quinuclidines,pyridines and piperidines,their preparation and antidotes against organophosphorus and carbamate poisoning containing them
US4644003A (en) * 1985-04-03 1987-02-17 Research Corporation 3-quinuclidinol esters, useful as antagonists of muscarinic acetylcholine receptors
US4675326A (en) * 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
US4843074A (en) * 1988-05-17 1989-06-27 Marion Laboratories, Inc. 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts
IT1230881B (it) * 1989-06-20 1991-11-08 Angeli Inst Spa Derivati del r(-) 3-chinuclidinolo
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
DE69132735T2 (de) * 1990-09-06 2002-05-29 Pfizer Inc., New York Anti-muscarin bronchodilatoren
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
GB9119705D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic compounds
HUT76289A (en) 1994-02-10 1997-07-28 Yamanouchi Pharma Co Ltd Carbamate derivative and medicinal composition containing the same
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
DE69615214T2 (de) * 1995-10-13 2002-06-27 Banyu Pharmaceutical Co., Ltd. Substituierte heteroaromatische derivate
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) * 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
US6916828B2 (en) 2000-06-27 2005-07-12 Laboratorios S.A.L.V.A.T., S.A. Carbamates derivatived from arylakylamines
RU2296762C2 (ru) 2000-12-22 2007-04-10 Альмиралль Продесфарма Аг Карбаматы хинуклидина, способы их получения и фармацевтическая композиция на их основе
DK1353919T3 (da) * 2000-12-28 2006-11-20 Almirall Prodesfarma Ag Hidtil ukendte quinuclidinderivater og medicinale sammensætninger indeholdende samme

Also Published As

Publication number Publication date
SK7992003A3 (en) 2004-08-03
EE05404B1 (et) 2011-04-15
PT1353919E (pt) 2006-11-30
AU2002238471B2 (en) 2007-06-28
UA75626C2 (en) 2006-05-15
MY136067A (en) 2008-08-29
US7893087B2 (en) 2011-02-22
CN1250545C (zh) 2006-04-12
CN1487938A (zh) 2004-04-07
US20070129398A1 (en) 2007-06-07
IL156558A (en) 2009-06-15
DE60121813D1 (de) 2006-09-07
CY1105719T1 (el) 2010-12-22
NZ526674A (en) 2005-03-24
IL156558A0 (en) 2004-01-04
RU2003123120A (ru) 2005-01-10
CA2433128C (en) 2010-05-25
KR100869721B1 (ko) 2008-11-21
ES2266291T3 (es) 2007-03-01
ATE334128T1 (de) 2006-08-15
NO20033002L (no) 2003-06-30
HUP0303524A3 (en) 2008-03-28
AR032072A1 (es) 2003-10-22
WO2002053564A3 (en) 2002-10-31
CZ20031812A3 (en) 2004-05-12
CA2433128A1 (en) 2002-07-11
CZ301209B6 (cs) 2009-12-09
US7122558B2 (en) 2006-10-17
EE200300312A (et) 2003-10-15
JP4295985B2 (ja) 2009-07-15
EP1353919B1 (en) 2006-07-26
RU2282629C2 (ru) 2006-08-27
ZA200305008B (en) 2005-01-26
SK287414B6 (sk) 2010-09-07
HK1055739A1 (en) 2004-01-21
US20040072863A1 (en) 2004-04-15
WO2002053564A2 (en) 2002-07-11
BG107950A (bg) 2004-03-31
SI1353919T1 (sl) 2006-12-31
JP2004517123A (ja) 2004-06-10
DE60121813T2 (de) 2007-09-20
US20100234332A1 (en) 2010-09-16
KR20030067726A (ko) 2003-08-14
DK1353919T3 (da) 2006-11-20
BG66162B1 (bg) 2011-09-30
US20070105897A1 (en) 2007-05-10
US7879874B2 (en) 2011-02-01
PL363807A1 (en) 2004-11-29
NO20033002D0 (no) 2003-06-30
HUP0303524A2 (hu) 2004-01-28
PE20020721A1 (es) 2002-10-01
NO328772B1 (no) 2010-05-10
BR0116624A (pt) 2003-12-23
MXPA03005862A (es) 2005-09-08
EP1353919A2 (en) 2003-10-22

Similar Documents

Publication Publication Date Title
ECSP034672A (es) Derivados de quinuclidina novedosos y composiciones medicinales que los contienen
AR035892A1 (es) Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos
MX9303981A (es) Nuevos compuestos farmaceuticos, proceso para su preparacion y composicion farmaceutica que los contiene.
CO5060482A1 (es) Derivados terapeuticos de biarilo
AR007077A1 (es) Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento
MX9203122A (es) Compuestos analogos de distamicina a y composiciones farmaceuticas que los contienen.
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
ES370394A1 (es) Procedimiento para la preparacion de nuevas 5-11-dihidro-6h-pirido (2,3-b) (1,4) benzodiazepin-6-ona y sus sales.
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
SE8307133D0 (sv) Carboxamido-derivatives of 5h-1,3,4-thiadiazolo(3,2-a)pyrimidines and process for their preparation
AR012622A1 (es) Inhibidores de proteasas, procedimiento para su preparacion, composicion farmaceutica que los comprende y el uso de los mismos en la fabricacion de unmedicamento
AR008291A1 (es) Derivados de tetrahidroisoquinolina, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso para la preparacionde un medicamento.
AR062405A1 (es) Derivados de isoindol
ES8503667A1 (es) Un procedimiento para la preparacion de nuevos derivados de 2-oxo-imidazolina.
AR044662A1 (es) Compuestos de azetidina
MX9307946A (es) Derivados de amina secundaria ciclica, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso.
MX9206169A (es) Derivados de quinoleina, su preparacion y su aplicacion en terapeutica.
HRP20080338T3 (hr) Novi kvaternizirani kinuklidinski esteri
KR910007928A (ko) 신규 벤조[1,8] 나프티리딘 유도체, 그의 제조 및 그를 함유하는 조성물
GB1507717A (en) Benz(de)isoquinoline derivatives
ES2012648A6 (es) Procedimiento para la preparacion de nuevos derivados de 1,4-benzoxazina y 1,4-benzotiazina.
GB1062714A (en) -ß-(4'-acyloxy-4'-piperidyl)-ketones
ES484616A1 (es) Un procedimiento para preparar nuevos derivados de pirrolil-piridazin-amina
IL66835A0 (en) Triazoloquinazolone derivatives and their salts,their preparation,their use as medicaments and the compositions containing them